SARS-CoV-2 (CoV-2) myocardial injury in patients with acute on chronic heart failure (CHF) at index hospitalization has been well-characterized. Though post-acute COVID-19 (PAC) hospitalization(s) is less investigated despite evidence that CoV-2 induced inflammatory response persists for up to 3 months after initial infection.

Management of acute and long-term COVID-19 cardiovascular syndrome is challenging and should involve a multidisciplinary team including cardiologists, intensive care specialists, infectious disease specialists, and cardiothoracic surgery specialists. A number of promising therapies were investigated during the pandemic. This chapter aims to review the best available data on acute and long-term treatment options of COVID-19 cardiovascular syndrome.